Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel

Vascular malformations are common vascular lesions in infants and seriously affect their health and quality of life. Vascular sclerotherapy is an effective treatment for vascular malformations. However, current sclerosants have difficulty achieving both high efficiency and low toxicity, and their do...

Full description

Saved in:
Bibliographic Details
Main Authors: Jizhuang Ma, Wenhan Li, Yu Ding, Yongfeng Chen, Xiaoyu Huang, Tong Yu, Di Song, Haoran Niu, Bao Li, Huichao Xie, Keda Zhang, Tianzhi Yang, Xiaoyun Zhao, Xinggang Yang, Pingtian Ding
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Materials Today Bio
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S259000642400437X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846123380948860928
author Jizhuang Ma
Wenhan Li
Yu Ding
Yongfeng Chen
Xiaoyu Huang
Tong Yu
Di Song
Haoran Niu
Bao Li
Huichao Xie
Keda Zhang
Tianzhi Yang
Xiaoyun Zhao
Xinggang Yang
Pingtian Ding
author_facet Jizhuang Ma
Wenhan Li
Yu Ding
Yongfeng Chen
Xiaoyu Huang
Tong Yu
Di Song
Haoran Niu
Bao Li
Huichao Xie
Keda Zhang
Tianzhi Yang
Xiaoyun Zhao
Xinggang Yang
Pingtian Ding
author_sort Jizhuang Ma
collection DOAJ
description Vascular malformations are common vascular lesions in infants and seriously affect their health and quality of life. Vascular sclerotherapy is an effective treatment for vascular malformations. However, current sclerosants have difficulty achieving both high efficiency and low toxicity, and their dosing forms make it difficult to achieve long-term retention in the affected blood vessels. Therefore, exploring a safe and effective sclerosant and its delivery strategy is the key to clinical sclerotherapy. To address the above issues, this study developed sclerosants that could form an in-situ gel based on a dual mechanism of vascular injury and plasmin (PLA) inhibition. By linking the non-ionic surfactant sclerosant polyoxyethylene alkyl ether (PAs) and the PLA inhibitor tranexamic acid (TA) through an ester bond, a cationic surfactant sclerosant polyoxyethylene alkylether tranexamate derivatives (PATDs) were constructed. The cationic charge of PATDs enhanced its cytotoxicity to HUVEC-TIE2-L914F cells, and the ester bond of PATDs could be degraded by esterase in the blood, reducing its systemic toxicity. The degradation product TA inhibited the activation of the PLA-matrix metalloproteinase (MMPs) system induced by vascular injury, thereby promoting the deposition of collagen and the proliferation and differentiation of fibroblasts to promote vascular fibrosis. In addition, an injectable solution (PATDs/GA) was prepared by mixing PATDs with glycerol formaldehyde (GA), and PATDs/GA could form a low-molecular-weight gel automatically in an aqueous solution, which was beneficial to increase its retention in the affected blood vessels and reduce the risk of drug entering non-targeted sites. At the same time, this gel automatically dissolved, reducing the risk of immune rejection caused by long-term retention. This study provided a new and precise approach for the treatment of vascular sclerosis with high efficiency and low toxicity.
format Article
id doaj-art-fa5cf9c5590d4c4a9922c0a3cdc3c8c1
institution Kabale University
issn 2590-0064
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Materials Today Bio
spelling doaj-art-fa5cf9c5590d4c4a9922c0a3cdc3c8c12024-12-14T06:32:29ZengElsevierMaterials Today Bio2590-00642024-12-0129101376Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gelJizhuang Ma0Wenhan Li1Yu Ding2Yongfeng Chen3Xiaoyu Huang4Tong Yu5Di Song6Haoran Niu7Bao Li8Huichao Xie9Keda Zhang10Tianzhi Yang11Xiaoyun Zhao12Xinggang Yang13Pingtian Ding14School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China; College of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, ChinaUltrasound Department, Shengjing Hospital, China Medical University, Shenyang, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaCollege of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, ChinaCollege of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, ChinaDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, Husson University, Bangor, ME, USASchool of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China; Corresponding author. School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China.College of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, China; School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China; Corresponding author. College of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, China.Vascular malformations are common vascular lesions in infants and seriously affect their health and quality of life. Vascular sclerotherapy is an effective treatment for vascular malformations. However, current sclerosants have difficulty achieving both high efficiency and low toxicity, and their dosing forms make it difficult to achieve long-term retention in the affected blood vessels. Therefore, exploring a safe and effective sclerosant and its delivery strategy is the key to clinical sclerotherapy. To address the above issues, this study developed sclerosants that could form an in-situ gel based on a dual mechanism of vascular injury and plasmin (PLA) inhibition. By linking the non-ionic surfactant sclerosant polyoxyethylene alkyl ether (PAs) and the PLA inhibitor tranexamic acid (TA) through an ester bond, a cationic surfactant sclerosant polyoxyethylene alkylether tranexamate derivatives (PATDs) were constructed. The cationic charge of PATDs enhanced its cytotoxicity to HUVEC-TIE2-L914F cells, and the ester bond of PATDs could be degraded by esterase in the blood, reducing its systemic toxicity. The degradation product TA inhibited the activation of the PLA-matrix metalloproteinase (MMPs) system induced by vascular injury, thereby promoting the deposition of collagen and the proliferation and differentiation of fibroblasts to promote vascular fibrosis. In addition, an injectable solution (PATDs/GA) was prepared by mixing PATDs with glycerol formaldehyde (GA), and PATDs/GA could form a low-molecular-weight gel automatically in an aqueous solution, which was beneficial to increase its retention in the affected blood vessels and reduce the risk of drug entering non-targeted sites. At the same time, this gel automatically dissolved, reducing the risk of immune rejection caused by long-term retention. This study provided a new and precise approach for the treatment of vascular sclerosis with high efficiency and low toxicity.http://www.sciencedirect.com/science/article/pii/S259000642400437XVascular malformationsSclerotherapyTranexamic acidPolyoxyethylene alkylether tranexamate derivativesPlasminLow-molecular-weight hydrogel
spellingShingle Jizhuang Ma
Wenhan Li
Yu Ding
Yongfeng Chen
Xiaoyu Huang
Tong Yu
Di Song
Haoran Niu
Bao Li
Huichao Xie
Keda Zhang
Tianzhi Yang
Xiaoyun Zhao
Xinggang Yang
Pingtian Ding
Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel
Materials Today Bio
Vascular malformations
Sclerotherapy
Tranexamic acid
Polyoxyethylene alkylether tranexamate derivatives
Plasmin
Low-molecular-weight hydrogel
title Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel
title_full Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel
title_fullStr Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel
title_full_unstemmed Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel
title_short Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel
title_sort enhanced sclerotherapy for vascular malformations a dual mechanism approach using in situ forming patds gel
topic Vascular malformations
Sclerotherapy
Tranexamic acid
Polyoxyethylene alkylether tranexamate derivatives
Plasmin
Low-molecular-weight hydrogel
url http://www.sciencedirect.com/science/article/pii/S259000642400437X
work_keys_str_mv AT jizhuangma enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT wenhanli enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT yuding enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT yongfengchen enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT xiaoyuhuang enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT tongyu enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT disong enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT haoranniu enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT baoli enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT huichaoxie enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT kedazhang enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT tianzhiyang enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT xiaoyunzhao enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT xinggangyang enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel
AT pingtianding enhancedsclerotherapyforvascularmalformationsadualmechanismapproachusinginsituformingpatdsgel